Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has become a cornerstone of medical weight loss, with clinical trials showing an average weight reduction of 15% over one year in patients with obesity. Many people ask whether brand-name Wegovy or similar medications can truly deliver lasting results. PlexusDx offers compounded semaglutide injections as a clinically equivalent, more affordable alternative available across all 50 states.

How Semaglutide Works for Weight Loss

Semaglutide is a GLP-1 receptor agonist, a medication class that mimics a natural hormone your body produces after eating. When semaglutide activates GLP-1 receptors in the brain, it signals fullness more quickly and reduces appetite signals over time. This dual effect—early satiety plus decreased hunger—helps many patients consume fewer calories without the constant mental effort of traditional dieting.

The medication also slows how fast your stomach empties food into the small intestine, prolonging the sensation of being full after meals. This mechanism is why patients often report losing interest in foods they previously craved. Clinical data demonstrates that semaglutide's weight-loss benefit appears within the first 4–8 weeks, with steady reductions continuing over 12 months of consistent use.

Wegovy vs. Compounded Semaglutide: What You Should Know

Wegovy is a brand-name semaglutide injection manufactured and distributed by Novo Nordisk at premium pricing, often exceeding $1,000 per month even with insurance coverage. Compounded semaglutide provides the same active ingredient—semaglutide—formulated by licensed 503A compounding pharmacies and prescribed by physicians to match your individual needs. The chemical composition and mechanism of action are identical; the key difference lies in manufacturing oversight, supply chain, and cost.

PlexusDx partners with licensed 503A compounding pharmacies to deliver semaglutide injections starting at $149 per month, with pricing that does not increase as your dose advances. Brand Wegovy requires insurance approval or out-of-pocket cash payment, whereas PlexusDx serves all 50 states without insurance requirements, membership fees, or insurance pre-authorization delays. Many patients find compounded options reduce access barriers while maintaining clinical efficacy and safety standards.

Weight Loss Results and Realistic Expectations

Clinical trials of semaglutide show an average weight reduction of 10–15% of baseline body weight over 68 weeks among people with obesity, with some patients losing significantly more depending on their starting weight, adherence, and lifestyle factors. Individual results vary considerably; some patients lose 20–30 pounds in their first three months, while others see gradual, steady progress over six months or longer. The rate of weight loss often correlates with how consistently patients use the medication and whether they combine it with modest dietary adjustments and physical activity.

Weight loss typically plateaus after 12–16 months of continuous treatment, at which point many people maintain their new weight on a stable dose without further decline. This plateau reflects a new physiological equilibrium rather than treatment failure. PlexusDx patients who pursue genetic testing via the Precision Peptide Genetic Test can identify their individual peptide-pathway predispositions, helping personalize both medication selection and lifestyle strategy for optimized outcomes.

Side Effects, Safety, and When to Seek Medical Guidance

Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation in the first 4–6 weeks. These effects typically subside as your body adapts to the medication, though some patients continue to experience mild nausea with certain foods. Serious but rare side effects include pancreatitis, gallbladder issues, and thyroid concerns; anyone with a personal or family history of medullary thyroid cancer should avoid GLP-1 medications entirely.

Because semaglutide slows gastric emptying and can reduce appetite for liquids as well as solids, dehydration risk increases—consistent water intake is essential. Patients should monitor for signs of severe abdominal pain, persistent vomiting, vision changes, or signs of low blood sugar (if combining with diabetes medications). PlexusDx recommends working with a licensed physician who reviews your full medical history before starting compounded semaglutide and provides ongoing monitoring, especially during dose adjustments.

Genetic Testing and Personalized Medication Selection

Not everyone responds identically to semaglutide alone; some patients benefit more from tirzepatide (a dual GLP-1/GIP agonist) or from combination approaches. PlexusDx offers the Precision Peptide Genetic Test, which analyzes your unique peptide-pathway genetics across 14 metabolic pathways, 49 peptides, and 150+ genetic insights. Key variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 influence how your body responds to GLP-1 and GIP signaling, appetite regulation, and metabolic rate.

By identifying your genetic predispositions, PlexusDx helps your physician select whether semaglutide, tirzepatide, or a combination approach (such as GLP-Squared) offers the highest likelihood of meaningful weight loss for your body. This precision approach moves beyond trial-and-error medication selection and can reduce time spent on suboptimal therapy. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment, providing a cost-effective way to optimize your personalized weight loss protocol.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as brand-name Wegovy?

Yes. Compounded semaglutide from licensed 503A pharmacies contains the identical active ingredient and works through the same biological mechanism as Wegovy. Clinical efficacy depends on consistent dosing and adherence rather than brand name. PlexusDx medications are prescribed by licensed physicians and formulated to pharmaceutical standards, ensuring potency and safety.

How much weight can I realistically lose on semaglutide?

Clinical trials show average weight loss of 10–15% of baseline body weight over approximately one year, with some patients losing significantly more. Results vary based on starting weight, adherence, diet, and exercise. PlexusDx patients can access the Precision Peptide Genetic Test to identify their unique metabolic predispositions and optimize medication selection for personalized outcomes.

Why is PlexusDx compounded semaglutide more affordable than Wegovy?

PlexusDx partners with licensed 503A compounding pharmacies, which operate at lower overhead than large pharmaceutical manufacturers and distributors. Compounded semaglutide starts at $149 per month with no insurance required, no membership fees, and pricing that remains flat regardless of dose level. PlexusDx serves all 50 states and accepts HSA/FSA payments, making treatment accessible and affordable.

What are the most common side effects, and how long do they last?

Nausea, vomiting, constipation, and diarrhea are most common, particularly during the first 4–6 weeks as your body adjusts. These effects typically improve significantly after the initial dose escalation phase. Staying hydrated and eating smaller, lower-fat meals can reduce nausea. Serious side effects are rare but require immediate medical attention; your PlexusDx physician monitors your response at every stage.

How can the Precision Peptide Genetic Test help me achieve better weight loss results?

PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and identifies variants in GLP1R, GIPR, FTO, MC4R, and 45 other peptides that influence your appetite, energy expenditure, and medication response. This genetic insight helps your physician choose whether semaglutide alone, tirzepatide, or a combination therapy offers the best outcome for your unique biology. The test costs $99 after your first month and removes guesswork from medication selection.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves